The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Cimoxatone     3-[[4-[5-(methoxymethyl)-2- oxo-1,3...

Synonyms: Cimoxatono, Cimoxatonum, SureCN198104, CHEMBL2104092, LS-38737, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

High impact information on MD 780515

 

Biological context of MD 780515

 

Associations of MD 780515 with other chemical compounds

 

Gene context of MD 780515

 

Analytical, diagnostic and therapeutic context of MD 780515

  • Single simultaneous time point determinations revealed 10-to 20-fold lower concentrations of cimoxatone and its metabolite in CSF compared to plasma 2 h after treatment [3].

References

  1. Oral absorption and concentration-effect relationship of tyramine with and without cimoxatone, a type-A specific inhibitor of monoamine oxidase. Dollery, C.T., Brown, M.J., Davies, D.S., Lewis, P.J., Strolin-Benedetti, M. Clin. Pharmacol. Ther. (1983) [Pubmed]
  2. The metabolism of dopamine by both forms of monoamine oxidase in the rat brain and its inhibition by cimoxatone. Fowler, C.J., Benedetti, M.S. J. Neurochem. (1983) [Pubmed]
  3. Rhesus monkey cerebrospinal fluid amine metabolite changes following treatment with the reversible monoamine oxidase type-A inhibitor cimoxatone. Garrick, N.A., Seppala, T., Linnoila, M., Murphy, D.L. Psychopharmacology (Berl.) (1985) [Pubmed]
  4. Plasma protein binding of the reversible type A MAO inhibitor cimoxatone (MD 780515). Rovei, V., Chanoine, F., Strolin Benedetti, M., Zini, R., Tillement, J.P. Biochem. Pharmacol. (1983) [Pubmed]
  5. Pharmacokinetic and relative bioavailability studies of cimoxatone in humans. Rovei, V., Mitchard, M., Strolin Benedetti, M., Kendall, M.J. International journal of clinical pharmacology, therapy, and toxicology. (1984) [Pubmed]
  6. SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition. Kan, J.P., Steinberg, R., Mouget-Goniot, C., Worms, P., Bizière, K. J. Pharmacol. Exp. Ther. (1987) [Pubmed]
  7. Determination of 2-phenylethylamine in rat brain after MAO inhibitors, and in human CSF and urine by capillary GC and chemical ionization MS. Lauber, J., Waldmeier, P.C. J. Neural Transm. (1984) [Pubmed]
  8. Basic and clinical aspects of the activity of the new monoamine oxidase inhibitors. Delini-Stula, A., Radeke, E., Waldmeier, P.C. Psychopharmacology series. (1988) [Pubmed]
  9. Comparison of monoamine oxidase-A inhibition by moclobemide in vitro and ex vivo in rats. Kettler, R., Da Prada, M., Burkard, W.P. Acta psychiatrica Scandinavica. Supplementum. (1990) [Pubmed]
  10. Effect of a reversible and selective MAO-A inhibitor (cimoxatone) on diurnal variation in plasma prolactin level in man. Strolin Benedetti, M., Eschalier, A., Lesage, A., Dordain, G., Rovei, V., Zarifian, E., Dostert, P. Eur. J. Clin. Pharmacol. (1984) [Pubmed]
 
WikiGenes - Universities